MAPT and supranuclear palsy, progressive, 1: Similarly to other tauopathies, such as progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD), CSF Tau and p-Tau levels were not elevated in individuals with pathogenic variants in MAPT indicating that Tau levels do not serve as a biomarker for MAPT-associated FTD [51].